<DOC>
	<DOC>NCT00004404</DOC>
	<brief_summary>OBJECTIVES: Determine the effectiveness of the combined use of clotrimazole and hydroxyurea on a specific panel of red cell characteristics in patients with sickle cell syndromes.</brief_summary>
	<brief_title>Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes</brief_title>
	<detailed_description>PROTOCOL OUTLINE: Patients receive oral hydroxyurea either once or twice daily plus oral clotrimazole twice daily after meals for 6 months. Patients are assessed at 3 and 6 months during treatment. Completion date provided represents the completion date of the grant per OOPD records</detailed_description>
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Sickle cell syndromes characterized by vasoocclusive crises sufficiently severe to require prophylactic therapy Three or more crises per year sufficiently severe to require hospitalization Stable dose of hydroxyurea for at least 4 months required Prior/Concurrent Therapy No treatment with any other antisickling agents within the past 4 months Biologic therapy: No transfusion within 90 days No concurrent chronic transfusions allowed (defined as more than one transfusion per month for 2 or more months) Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other: No chronic medications that alter neurologic, renal, or hepatic functions Patient Characteristics Performance status: Karnofsky 70100% Hematopoietic: WBC within normal limits Platelet count within normal limits Hepatic: No history of chronic liver disease Bilirubin less than 2 times normal SGOT and SGPT less than 2.5 times normal No severe hepatic damage Renal: Creatinine within normal limits No severe renal damage Neurologic: No severe neurologic impairment No recent or progressive neurologic impairment Other: Not pregnant Fertile patients must use effective contraception No allergies to hydroxyurea or clotrimazole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1998</verification_date>
	<keyword>genetic diseases and dysmorphic syndromes</keyword>
	<keyword>hematologic disorders</keyword>
	<keyword>rare disease</keyword>
	<keyword>sickle cell anemia</keyword>
</DOC>